Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic values of various clinical factors and genetic subtypes for diffuse large B-cell lymphoma patients: a retrospective analysis of 227 cases.

Asian Pacific journal of cancer prevention : APJCP - 1 Jan 2013

Zhou De, Xie Wan-Zhuo, Hu Ke-Yue, Huang Wei-Jia, Wei Guo-Qing, He Jing-Song, Shi Ji-Min, Luo Yi, Li Li, Zhu Jing-Jing, Zhang Jie, Lin Mao-Fang, Ye Xiu-Jin, Cai Zhen, Huang He

Abstract excerpt

AIM: To analyze the significance of different clinical factors for prognostic prediction in diffuse large B-cell lymphoma (DLBCL) patients. METHODS: Two hundred and twenty-seven DLBCL patients were retrospectively reviewed. Patients were managed with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen or rituximab plus the CHOP (RCHOP) regimen. RESULTS: Lactate dehydrogenase (LDH), β2-...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Murine-Derived
Share to beta 2-Microglobulin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Germinal Center

Share to L-Lactate Dehydrogenase

Share to Prednisone

Share to Rituximab

Share to Survival

Share to Vincristine

Source

Identifiers

PMID: 23621263
DOI: 10.7314/apjcp.2013.14.2.929

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic values of various clinical factors and genetic subtypes for diffuse large B-cell lymphoma patients: a retrospective analysis of 227 cases.PMID 23621263Read ↗

Diffuse Large B-cell lymphoma: Prognostic markers and their impact on therapy.Semantic proximity Read ↗

Molecular pathogenesis and treatment strategy in diffuse large B-cell lymphoma.Semantic proximity Read ↗

Clinical features and immunophenotypes of double-hit diffuse large B-cell lymphomaSemantic proximity Read ↗

Molecular pathogenesis of diffuse large B-cell lymphoma.Semantic proximity Read ↗

Genetic lesions in diffuse large B-cell lymphomas.Semantic proximity Read ↗

Molecular heterogeneity in diffuse large B-cell lymphoma and its implications in clinical diagnosis and treatment.Semantic proximity Read ↗

Molecular classification and therapeutics in diffuse large B-cell lymphomaSemantic proximity Read ↗

Diffuse large B-cell lymphoma.Semantic proximity Read ↗

Prognostic Analysis of Diffuse Large B-Cell Lymphoma Patients Based on Clinical Characteristics, TP53 Mutation Status, and Number of Co-mutated GenesSemantic proximity Read ↗

Clinicopathological features and prognostic factors of rare primary bone marrow diffuse large B cell lymphomaSemantic proximity Read ↗

[Clinical Features and Prognosis of Patients with Primary Extranodal Diffuse Large B-Cell Lymphoma].Semantic proximity Read ↗

Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.